SELLAS Life Sciences Group
NEWS
A roundup of last week’s top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
Biopharma and life sciences companies continue to strengthen their executive teams and boards with this week’s Movers & Shakers.
It was a relatively quiet week for clinical trial announcements. Here’s a look.
Positive results from Sellas Life Sciences Group’s Phase I/II trial using galinpepimut-S (GPS) as a combination therapy with pembrolizumab (Keytruda®) were announced Wednesday, shortly after similarly positive news was issued from a combination study in which GPS was evaluated as a treatment for mesothelioma.
To wrap up Breast Cancer Awareness Month, BioSpace gathered some examples of recent breakthroughs in breast cancer treatment.
Last week was a particularly busy week for biopharma companies to release information about ongoing clinical trials. Here’s a look.
Every week brings news of clinical trials, ranging from launches, first-patient dosing, full enrollment, interim data or final data. Here’s a look at some of the clinical trial news from last week.
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
After nearly a year without a permanent chief executive officer Advaxis, Inc. has a new hand on the wheel. This morning the company announced Kenneth A. Berlin will take over the helm of the company as president and CEO effective immediately.
JOBS
IN THE PRESS